نتایج جستجو برای: a9 everolimus stents drug
تعداد نتایج: 602739 فیلتر نتایج به سال:
I n this issue, Yamaji et al 1 report the very long-term (15-year) outcomes of patients treated successfully with balloon angioplasty (BA) compared with bare-metal stent implantation (BMS). Considering the major progresses made in interventional cardiology since the advent of BA, it would be reasonable to question what relevance these data have in the era of thirdand fourth-generation drug-elut...
INTRODUCTION Prolonged dual anti-platelet therapy (DAPT) may cause excess bleeding in certain patients. The biolimus-A9 drug-coated stent (BA9-DCS) has a rapid drug-elution profile allowing shortened DAPT. Data were gathered on the early experience implanting this stent in drug-eluting stent eligible patients deemed to be at high risk of bleeding. BACKGROUND AND METHODS The demographics, proc...
BACKGROUND Stent thrombosis (ST) is a rare but serious complication following percutaneous coronary intervention. Analysis of thrombus composition from patients undergoing catheter thrombectomy may provide important insights into the pathological processes leading to thrombus formation. We performed a large-scale multicentre study to evaluate thrombus specimens in patients with ST across Europe...
A mong the rare complications after percutaneous coronary intervention, coronary artery aneurysms (CAA) reportedly have an incidence of 0.3% to 6.0%. The detection of CAAs vary from 3 days to up to 4 years after drug-eluting stent (DES) and from 6 days to up to 6 years after baremetal stents (BMS) implantation. Associated factors include residual dissection and deep arterial wall injury caused ...
BACKGROUND Although effective coverage of challenging coronary lesions has warranted the use of overlapping drug-eluting stents, the histopathological response to stent overlap is unknown. METHODS AND RESULTS The arterial reaction to overlapping Cypher or Taxus drug-eluting stents was examined in rabbits with bare metal stents, BxVelocity or Express, serving as controls. Single iliac artery b...
BACKGROUND Everolimus, an active immunosuppressive and antiproliferative agent of the same family as sirolimus (rapamycin), has demonstrated significant reduction of neointimal proliferation in animal studies. The First Use To Underscore restenosis Reduction with Everolimus (FUTURE) I trial was the first in-human experience to evaluate the safety and efficacy of everolimus-eluting stents (EES),...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید